Patient Enrolment Completed for EFTISARC-NEO Phase II Trial

Core Insights - Immutep Limited has completed patient enrolment in the EFTISARC-NEO trial, which evaluates eftilagimod alpha in combination with radiotherapy and KEYTRUDA® for patients with resectable soft tissue sarcoma [1][2][4] Group 1: Trial Details - The Phase II trial, conducted by the Maria Skłodowska-Curie National Research Institute of Oncology, has successfully enrolled 40 patients [2] - Positive data from the trial was presented at the CTOS Annual Meeting in November 2024, showing a greater than three-fold increase in tumour hyalinization/fibrosis (median 50%) compared to a historical median of 15% from radiotherapy alone [3] - The treatment has shown safety with no grade ≥3 toxicities related to efti and pembrolizumab [4] Group 2: Future Expectations - Data updates from the EFTISARC-NEO trial are anticipated in 2025 [4][8]